41° Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

102.90 -1.27 (-1.22%)

Streaming Delayed Price Updated: 3:09 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Preview: Celcuity's Earnings ↗

March 22, 2022

Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 17, 2022

Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

March 16, 2022

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

March 02, 2022

MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity ↗

January 18, 2022

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program...

Via Benzinga

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update

January 18, 2022

- FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients - On track to finalize Phase 3...

From Celcuity Inc.

Via AccessWire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 22, 2021

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...

Via Benzinga

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium

December 10, 2021

78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity...

From Celcuity Inc.

Via AccessWire

Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium

December 02, 2021

MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

November 29, 2021

MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial

November 15, 2021

MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

November 09, 2021

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 08, 2021

- On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 - Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the...

From Celcuity Inc.

Via AccessWire

Topics Intellectual Property

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

October 29, 2021

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases

October 18, 2021

From Celcuity Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗

October 08, 2021

Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 ↗

September 07, 2021

Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:

Via Benzinga

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 09, 2021

- Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities - After follow-on offering,...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

August 05, 2021

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

August 02, 2021

MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for...

From Celcuity Inc.

Via AccessWire

Celcuity to Participate in the William Blair Biotech Focus Conference

July 08, 2021

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...

From Celcuity Inc.

Via AccessWire

58 Biggest Movers From Yesterday ↗

June 30, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) stock moved upwards by 93.55% to $24.33 during Tuesday's regular session. As of 12:30 EST, this security is trading at...

Via Benzinga

35 Stocks Moving In Tuesday's Mid-Day Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231...

Via Benzinga

Why Celcuity Stock Is Crashing Today ↗

June 29, 2021

The clinical-stage biotech announced the pricing of a secondary stock offering.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2....

Via Benzinga

22 Stocks Moving in Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Celcuity Inc. - Common Stock (NQ:CELC)

All News about Celcuity Inc. - Common Stock

Sections

Services